サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1316511

セファロスポリン系薬剤市場：セファロスポリン世代、薬剤投与、処方タイプ、用途別-2023～2030年の世界予測

Cephalosporin Drugs Market by Generation of Cephalosporin, Drug Administration, Prescription Type, Application - Cumulative Impact of COVID-19, Russia Ukraine Conflict, and High Inflation - Global Forecast 2023-2030
出版日: | 発行: 360iResearch | ページ情報: 英文 180 Pages | 納期: 即日から翌営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.76円
セファロスポリン系薬剤市場：セファロスポリン世代、薬剤投与、処方タイプ、用途別-2023～2030年の世界予測
出版日: 2023年06月12日
発行: 360iResearch
ページ情報: 英文 180 Pages
納期: 即日から翌営業日
ご注意事項 :
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 図表
  • 目次
概要

セファロスポリン系薬剤の世界市場は、2023年に113億7,000万米ドル、CAGR6.64%で大きく成長し、2030年には178億6,000万米ドルに達すると予測されています。

FPNVポジショニング・マトリックス

FPNVポジショニングマトリックスは世界のセファロスポリン系薬剤市場を評価するために不可欠です。事業戦略と製品満足度の主要指標を調査することで、ベンダーの包括的な評価を提供し、ユーザーは特定のニーズに基づいた情報をもとに意思決定を行うことができます。この高度な分析により、ベンダーは成功の度合いが異なる4つの象限に整理されます：フォアフロント（F）、パスファインダー（P）、ニッチ（N）、バイタル（V）です。

市場シェア分析

市場シェア分析では、特定の市場領域におけるベンダーの現状を洞察することができます。全体的な収益、顧客基盤、その他の主要指標に対するベンダーの貢献度を比較することで、企業が市場シェアを争う際に、自社の業績や直面している状況をより深く理解することができます。また、本分析では、調査した基準年において、特定のセクターがどの程度競合しているのか、蓄積、断片化の優位性、合併の特徴についても明らかにしています。

本レポートは、以下のポイントに関する洞察を提供します：

1.市場の浸透度：主要企業が提供する市場に関する包括的な情報を提供します。

2.市場の発展：有利な新興市場に関する詳細情報を提供し、市場の成熟セグメントにおける浸透度を分析します。

3.市場の多様化：新製品の上市、未開発地域、最近の開発、投資に関する詳細情報を提供します。

4.市場の動向：COVID-19、ロシア・ウクライナ紛争、高インフレの累積的な影響を包括的に理解することができます。

5.競合の評価と情報：主要企業の市場シェア、戦略、製品、認証、規制状況、特許状況、製造能力を網羅的に評価します。

6.製品開発およびイノベーション：将来技術、研究開発活動、画期的な製品開発に関する知的洞察を提供します。

本レポートは、以下のような質問にお答えします：

1.セファロスポリン系薬剤の世界市場規模および予測は？

2.予測期間中、世界のセファロスポリン系薬剤市場を形成するCOVID-19の阻害要因と影響は？

3.セファロスポリン系薬剤の世界市場において予測期間中に投資すべき製品/セグメント/用途/分野は？

4.セファロスポリン系薬剤の世界市場における競争戦略は？

5.セファロスポリン系薬剤の世界市場における技術動向と規制の枠組みは？

6.セファロスポリン系薬剤の世界市場における主要ベンダーの市場シェアは？

7.セファロスポリン系薬剤の世界市場への参入には、どのような形態や戦略的な動きが適していると考えられるか？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

  • 市場力学
    • 促進要因
      • 皮膚や尿路感染症などの細菌感染症の増加
      • 研究開発と臨床試験に継続的に注力
      • 併用療法の広範な応用
    • 抑制要因
      • セファロスポリン系薬剤に関連する副作用
    • 機会
      • 抗生物質の開発を促進するため、製薬会社や製薬団体による投資を増加
      • 抗生物質を支持する政府規制の改訂
    • 課題
      • 人々の意識の限界と農村部や僻地における需要と供給のアンバランス
  • 市場動向
  • COVID-19の累積的な影響
  • ロシア・ウクライナ紛争の累積的影響
  • 高インフレの累積的影響
  • ポーターのファイブフォース分析
  • バリューチェーンとクリティカルパス分析
  • 規制の枠組み
  • 顧客のカスタマイズ

第6章 セファロスポリン系薬剤市場：セファロスポリン世代別

  • イントロダクション
  • 第五世代
  • 第一世代
  • 第四世代
  • 第二世代
  • 第三世代

第7章 セファロスポリン系薬剤市場：薬剤投与別

  • イントロダクション
  • 注射
  • 経口

第8章 セファロスポリン系薬剤市場：処方タイプ別

  • イントロダクション
  • 一般用医薬品
  • 処方薬

第9章 セファロスポリン系薬剤市場：用途別

  • イントロダクション
  • 耳感染症
  • 気道感染症
  • 皮膚感染症
  • 尿路感染

第10章 南北アメリカのセファロスポリン系薬剤市場

  • イントロダクション
  • アルゼンチン
  • ブラジル
  • カナダ
  • メキシコ
  • 米国

第11章 アジア太平洋地域のセファロスポリン系薬剤市場

  • イントロダクション
  • オーストラリア
  • 中国
  • インド
  • インドネシア
  • 日本
  • マレーシア
  • フィリピン
  • シンガポール
  • 韓国
  • 台湾
  • タイ
  • ベトナム

第12章 欧州・中東・アフリカのセファロスポリン系薬剤市場

  • イントロダクション
  • デンマーク
  • エジプト
  • フィンランド
  • フランス
  • ドイツ
  • イスラエル
  • イタリア
  • オランダ
  • ナイジェリア
  • ノルウェー
  • ポーランド
  • カタール
  • ロシア
  • サウジアラビア
  • 南アフリカ
  • スペイン
  • スウェーデン
  • スイス
  • トルコ
  • アラブ首長国連邦
  • 英国

第13章 競合情勢

  • FPNVポジショニングマトリクス
  • 市場シェア分析：主要企業別
  • 競合シナリオ分析：主要企業別

第14章 掲載企業一覧

第15章 付録

  • ディスカッションガイド
  • ライセンスと価格について
図表

LIST OF FIGURES

  • FIGURE 1. CEPHALOSPORIN DRUGS MARKET RESEARCH PROCESS
  • FIGURE 2. CEPHALOSPORIN DRUGS MARKET SIZE, 2022 VS 2030
  • FIGURE 3. CEPHALOSPORIN DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. CEPHALOSPORIN DRUGS MARKET SIZE, BY GENERATION OF CEPHALOSPORIN, 2022 VS 2030 (%)
  • FIGURE 5. CEPHALOSPORIN DRUGS MARKET SIZE, BY DRUG ADMINISTRATION, 2022 VS 2030 (%)
  • FIGURE 6. CEPHALOSPORIN DRUGS MARKET SIZE, BY PRESCRIPTION TYPE, 2022 VS 2030 (%)
  • FIGURE 7. CEPHALOSPORIN DRUGS MARKET SIZE, BY APPLICATION, 2022 VS 2030 (%)
  • FIGURE 8. CEPHALOSPORIN DRUGS MARKET SIZE, BY REGION, 2022 VS 2030 (%)
  • FIGURE 9. CEPHALOSPORIN DRUGS MARKET DYNAMICS
  • FIGURE 10. CEPHALOSPORIN DRUGS MARKET SIZE, BY GENERATION OF CEPHALOSPORIN, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 11. CEPHALOSPORIN DRUGS MARKET SIZE, BY DRUG ADMINISTRATION, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 12. CEPHALOSPORIN DRUGS MARKET SIZE, BY PRESCRIPTION TYPE, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 13. CEPHALOSPORIN DRUGS MARKET SIZE, BY APPLICATION, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 14. AMERICAS CEPHALOSPORIN DRUGS MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 15. UNITED STATES CEPHALOSPORIN DRUGS MARKET SIZE, BY STATE, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC CEPHALOSPORIN DRUGS MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 17. EUROPE, MIDDLE EAST & AFRICA CEPHALOSPORIN DRUGS MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 18. CEPHALOSPORIN DRUGS MARKET, FPNV POSITIONING MATRIX, 2022
  • FIGURE 19. CEPHALOSPORIN DRUGS MARKET SHARE, BY KEY PLAYER, 2022

LIST OF TABLES

  • TABLE 1. CEPHALOSPORIN DRUGS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2022
  • TABLE 3. CEPHALOSPORIN DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. CEPHALOSPORIN DRUGS MARKET SIZE, BY GENERATION OF CEPHALOSPORIN, 2018-2030 (USD MILLION)
  • TABLE 5. CEPHALOSPORIN DRUGS MARKET SIZE, BY FIFTH-GENERATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 6. CEPHALOSPORIN DRUGS MARKET SIZE, BY FIRST-GENERATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 7. CEPHALOSPORIN DRUGS MARKET SIZE, BY FOURTH-GENERATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 8. CEPHALOSPORIN DRUGS MARKET SIZE, BY SECOND-GENERATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. CEPHALOSPORIN DRUGS MARKET SIZE, BY THIRD-GENERATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. CEPHALOSPORIN DRUGS MARKET SIZE, BY DRUG ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 11. CEPHALOSPORIN DRUGS MARKET SIZE, BY INJECTION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. CEPHALOSPORIN DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. CEPHALOSPORIN DRUGS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 14. CEPHALOSPORIN DRUGS MARKET SIZE, BY OTC DRUGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. CEPHALOSPORIN DRUGS MARKET SIZE, BY PRESCRIPTION DRUGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. CEPHALOSPORIN DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 17. CEPHALOSPORIN DRUGS MARKET SIZE, BY EAR INFECTION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. CEPHALOSPORIN DRUGS MARKET SIZE, BY RESPIRATORY TRACT INFECTION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. CEPHALOSPORIN DRUGS MARKET SIZE, BY SKIN INFECTION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. CEPHALOSPORIN DRUGS MARKET SIZE, BY URINARY TRACT INFECTION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. AMERICAS CEPHALOSPORIN DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 22. AMERICAS CEPHALOSPORIN DRUGS MARKET SIZE, BY GENERATION OF CEPHALOSPORIN, 2018-2030 (USD MILLION)
  • TABLE 23. AMERICAS CEPHALOSPORIN DRUGS MARKET SIZE, BY DRUG ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 24. AMERICAS CEPHALOSPORIN DRUGS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 25. AMERICAS CEPHALOSPORIN DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 26. ARGENTINA CEPHALOSPORIN DRUGS MARKET SIZE, BY GENERATION OF CEPHALOSPORIN, 2018-2030 (USD MILLION)
  • TABLE 27. ARGENTINA CEPHALOSPORIN DRUGS MARKET SIZE, BY DRUG ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 28. ARGENTINA CEPHALOSPORIN DRUGS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 29. ARGENTINA CEPHALOSPORIN DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 30. BRAZIL CEPHALOSPORIN DRUGS MARKET SIZE, BY GENERATION OF CEPHALOSPORIN, 2018-2030 (USD MILLION)
  • TABLE 31. BRAZIL CEPHALOSPORIN DRUGS MARKET SIZE, BY DRUG ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 32. BRAZIL CEPHALOSPORIN DRUGS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 33. BRAZIL CEPHALOSPORIN DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 34. CANADA CEPHALOSPORIN DRUGS MARKET SIZE, BY GENERATION OF CEPHALOSPORIN, 2018-2030 (USD MILLION)
  • TABLE 35. CANADA CEPHALOSPORIN DRUGS MARKET SIZE, BY DRUG ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 36. CANADA CEPHALOSPORIN DRUGS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 37. CANADA CEPHALOSPORIN DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 38. MEXICO CEPHALOSPORIN DRUGS MARKET SIZE, BY GENERATION OF CEPHALOSPORIN, 2018-2030 (USD MILLION)
  • TABLE 39. MEXICO CEPHALOSPORIN DRUGS MARKET SIZE, BY DRUG ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 40. MEXICO CEPHALOSPORIN DRUGS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 41. MEXICO CEPHALOSPORIN DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 42. UNITED STATES CEPHALOSPORIN DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 43. UNITED STATES CEPHALOSPORIN DRUGS MARKET SIZE, BY GENERATION OF CEPHALOSPORIN, 2018-2030 (USD MILLION)
  • TABLE 44. UNITED STATES CEPHALOSPORIN DRUGS MARKET SIZE, BY DRUG ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 45. UNITED STATES CEPHALOSPORIN DRUGS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 46. UNITED STATES CEPHALOSPORIN DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 47. ASIA-PACIFIC CEPHALOSPORIN DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 48. ASIA-PACIFIC CEPHALOSPORIN DRUGS MARKET SIZE, BY GENERATION OF CEPHALOSPORIN, 2018-2030 (USD MILLION)
  • TABLE 49. ASIA-PACIFIC CEPHALOSPORIN DRUGS MARKET SIZE, BY DRUG ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 50. ASIA-PACIFIC CEPHALOSPORIN DRUGS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 51. ASIA-PACIFIC CEPHALOSPORIN DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 52. AUSTRALIA CEPHALOSPORIN DRUGS MARKET SIZE, BY GENERATION OF CEPHALOSPORIN, 2018-2030 (USD MILLION)
  • TABLE 53. AUSTRALIA CEPHALOSPORIN DRUGS MARKET SIZE, BY DRUG ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 54. AUSTRALIA CEPHALOSPORIN DRUGS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 55. AUSTRALIA CEPHALOSPORIN DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 56. CHINA CEPHALOSPORIN DRUGS MARKET SIZE, BY GENERATION OF CEPHALOSPORIN, 2018-2030 (USD MILLION)
  • TABLE 57. CHINA CEPHALOSPORIN DRUGS MARKET SIZE, BY DRUG ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 58. CHINA CEPHALOSPORIN DRUGS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 59. CHINA CEPHALOSPORIN DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 60. INDIA CEPHALOSPORIN DRUGS MARKET SIZE, BY GENERATION OF CEPHALOSPORIN, 2018-2030 (USD MILLION)
  • TABLE 61. INDIA CEPHALOSPORIN DRUGS MARKET SIZE, BY DRUG ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 62. INDIA CEPHALOSPORIN DRUGS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 63. INDIA CEPHALOSPORIN DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 64. INDONESIA CEPHALOSPORIN DRUGS MARKET SIZE, BY GENERATION OF CEPHALOSPORIN, 2018-2030 (USD MILLION)
  • TABLE 65. INDONESIA CEPHALOSPORIN DRUGS MARKET SIZE, BY DRUG ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 66. INDONESIA CEPHALOSPORIN DRUGS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 67. INDONESIA CEPHALOSPORIN DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 68. JAPAN CEPHALOSPORIN DRUGS MARKET SIZE, BY GENERATION OF CEPHALOSPORIN, 2018-2030 (USD MILLION)
  • TABLE 69. JAPAN CEPHALOSPORIN DRUGS MARKET SIZE, BY DRUG ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 70. JAPAN CEPHALOSPORIN DRUGS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 71. JAPAN CEPHALOSPORIN DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 72. MALAYSIA CEPHALOSPORIN DRUGS MARKET SIZE, BY GENERATION OF CEPHALOSPORIN, 2018-2030 (USD MILLION)
  • TABLE 73. MALAYSIA CEPHALOSPORIN DRUGS MARKET SIZE, BY DRUG ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 74. MALAYSIA CEPHALOSPORIN DRUGS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 75. MALAYSIA CEPHALOSPORIN DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 76. PHILIPPINES CEPHALOSPORIN DRUGS MARKET SIZE, BY GENERATION OF CEPHALOSPORIN, 2018-2030 (USD MILLION)
  • TABLE 77. PHILIPPINES CEPHALOSPORIN DRUGS MARKET SIZE, BY DRUG ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 78. PHILIPPINES CEPHALOSPORIN DRUGS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 79. PHILIPPINES CEPHALOSPORIN DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 80. SINGAPORE CEPHALOSPORIN DRUGS MARKET SIZE, BY GENERATION OF CEPHALOSPORIN, 2018-2030 (USD MILLION)
  • TABLE 81. SINGAPORE CEPHALOSPORIN DRUGS MARKET SIZE, BY DRUG ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 82. SINGAPORE CEPHALOSPORIN DRUGS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 83. SINGAPORE CEPHALOSPORIN DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 84. SOUTH KOREA CEPHALOSPORIN DRUGS MARKET SIZE, BY GENERATION OF CEPHALOSPORIN, 2018-2030 (USD MILLION)
  • TABLE 85. SOUTH KOREA CEPHALOSPORIN DRUGS MARKET SIZE, BY DRUG ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 86. SOUTH KOREA CEPHALOSPORIN DRUGS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 87. SOUTH KOREA CEPHALOSPORIN DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 88. TAIWAN CEPHALOSPORIN DRUGS MARKET SIZE, BY GENERATION OF CEPHALOSPORIN, 2018-2030 (USD MILLION)
  • TABLE 89. TAIWAN CEPHALOSPORIN DRUGS MARKET SIZE, BY DRUG ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 90. TAIWAN CEPHALOSPORIN DRUGS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 91. TAIWAN CEPHALOSPORIN DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 92. THAILAND CEPHALOSPORIN DRUGS MARKET SIZE, BY GENERATION OF CEPHALOSPORIN, 2018-2030 (USD MILLION)
  • TABLE 93. THAILAND CEPHALOSPORIN DRUGS MARKET SIZE, BY DRUG ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 94. THAILAND CEPHALOSPORIN DRUGS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 95. THAILAND CEPHALOSPORIN DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 96. VIETNAM CEPHALOSPORIN DRUGS MARKET SIZE, BY GENERATION OF CEPHALOSPORIN, 2018-2030 (USD MILLION)
  • TABLE 97. VIETNAM CEPHALOSPORIN DRUGS MARKET SIZE, BY DRUG ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 98. VIETNAM CEPHALOSPORIN DRUGS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 99. VIETNAM CEPHALOSPORIN DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 100. EUROPE, MIDDLE EAST & AFRICA CEPHALOSPORIN DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 101. EUROPE, MIDDLE EAST & AFRICA CEPHALOSPORIN DRUGS MARKET SIZE, BY GENERATION OF CEPHALOSPORIN, 2018-2030 (USD MILLION)
  • TABLE 102. EUROPE, MIDDLE EAST & AFRICA CEPHALOSPORIN DRUGS MARKET SIZE, BY DRUG ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 103. EUROPE, MIDDLE EAST & AFRICA CEPHALOSPORIN DRUGS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 104. EUROPE, MIDDLE EAST & AFRICA CEPHALOSPORIN DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 105. DENMARK CEPHALOSPORIN DRUGS MARKET SIZE, BY GENERATION OF CEPHALOSPORIN, 2018-2030 (USD MILLION)
  • TABLE 106. DENMARK CEPHALOSPORIN DRUGS MARKET SIZE, BY DRUG ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 107. DENMARK CEPHALOSPORIN DRUGS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 108. DENMARK CEPHALOSPORIN DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 109. EGYPT CEPHALOSPORIN DRUGS MARKET SIZE, BY GENERATION OF CEPHALOSPORIN, 2018-2030 (USD MILLION)
  • TABLE 110. EGYPT CEPHALOSPORIN DRUGS MARKET SIZE, BY DRUG ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 111. EGYPT CEPHALOSPORIN DRUGS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 112. EGYPT CEPHALOSPORIN DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 113. FINLAND CEPHALOSPORIN DRUGS MARKET SIZE, BY GENERATION OF CEPHALOSPORIN, 2018-2030 (USD MILLION)
  • TABLE 114. FINLAND CEPHALOSPORIN DRUGS MARKET SIZE, BY DRUG ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 115. FINLAND CEPHALOSPORIN DRUGS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 116. FINLAND CEPHALOSPORIN DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 117. FRANCE CEPHALOSPORIN DRUGS MARKET SIZE, BY GENERATION OF CEPHALOSPORIN, 2018-2030 (USD MILLION)
  • TABLE 118. FRANCE CEPHALOSPORIN DRUGS MARKET SIZE, BY DRUG ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 119. FRANCE CEPHALOSPORIN DRUGS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 120. FRANCE CEPHALOSPORIN DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 121. GERMANY CEPHALOSPORIN DRUGS MARKET SIZE, BY GENERATION OF CEPHALOSPORIN, 2018-2030 (USD MILLION)
  • TABLE 122. GERMANY CEPHALOSPORIN DRUGS MARKET SIZE, BY DRUG ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 123. GERMANY CEPHALOSPORIN DRUGS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 124. GERMANY CEPHALOSPORIN DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 125. ISRAEL CEPHALOSPORIN DRUGS MARKET SIZE, BY GENERATION OF CEPHALOSPORIN, 2018-2030 (USD MILLION)
  • TABLE 126. ISRAEL CEPHALOSPORIN DRUGS MARKET SIZE, BY DRUG ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 127. ISRAEL CEPHALOSPORIN DRUGS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 128. ISRAEL CEPHALOSPORIN DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 129. ITALY CEPHALOSPORIN DRUGS MARKET SIZE, BY GENERATION OF CEPHALOSPORIN, 2018-2030 (USD MILLION)
  • TABLE 130. ITALY CEPHALOSPORIN DRUGS MARKET SIZE, BY DRUG ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 131. ITALY CEPHALOSPORIN DRUGS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 132. ITALY CEPHALOSPORIN DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 133. NETHERLANDS CEPHALOSPORIN DRUGS MARKET SIZE, BY GENERATION OF CEPHALOSPORIN, 2018-2030 (USD MILLION)
  • TABLE 134. NETHERLANDS CEPHALOSPORIN DRUGS MARKET SIZE, BY DRUG ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 135. NETHERLANDS CEPHALOSPORIN DRUGS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 136. NETHERLANDS CEPHALOSPORIN DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 137. NIGERIA CEPHALOSPORIN DRUGS MARKET SIZE, BY GENERATION OF CEPHALOSPORIN, 2018-2030 (USD MILLION)
  • TABLE 138. NIGERIA CEPHALOSPORIN DRUGS MARKET SIZE, BY DRUG ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 139. NIGERIA CEPHALOSPORIN DRUGS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 140. NIGERIA CEPHALOSPORIN DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 141. NORWAY CEPHALOSPORIN DRUGS MARKET SIZE, BY GENERATION OF CEPHALOSPORIN, 2018-2030 (USD MILLION)
  • TABLE 142. NORWAY CEPHALOSPORIN DRUGS MARKET SIZE, BY DRUG ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 143. NORWAY CEPHALOSPORIN DRUGS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 144. NORWAY CEPHALOSPORIN DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 145. POLAND CEPHALOSPORIN DRUGS MARKET SIZE, BY GENERATION OF CEPHALOSPORIN, 2018-2030 (USD MILLION)
  • TABLE 146. POLAND CEPHALOSPORIN DRUGS MARKET SIZE, BY DRUG ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 147. POLAND CEPHALOSPORIN DRUGS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 148. POLAND CEPHALOSPORIN DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 149. QATAR CEPHALOSPORIN DRUGS MARKET SIZE, BY GENERATION OF CEPHALOSPORIN, 2018-2030 (USD MILLION)
  • TABLE 150. QATAR CEPHALOSPORIN DRUGS MARKET SIZE, BY DRUG ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 151. QATAR CEPHALOSPORIN DRUGS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 152. QATAR CEPHALOSPORIN DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 153. RUSSIA CEPHALOSPORIN DRUGS MARKET SIZE, BY GENERATION OF CEPHALOSPORIN, 2018-2030 (USD MILLION)
  • TABLE 154. RUSSIA CEPHALOSPORIN DRUGS MARKET SIZE, BY DRUG ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 155. RUSSIA CEPHALOSPORIN DRUGS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 156. RUSSIA CEPHALOSPORIN DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 157. SAUDI ARABIA CEPHALOSPORIN DRUGS MARKET SIZE, BY GENERATION OF CEPHALOSPORIN, 2018-2030 (USD MILLION)
  • TABLE 158. SAUDI ARABIA CEPHALOSPORIN DRUGS MARKET SIZE, BY DRUG ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 159. SAUDI ARABIA CEPHALOSPORIN DRUGS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 160. SAUDI ARABIA CEPHALOSPORIN DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 161. SOUTH AFRICA CEPHALOSPORIN DRUGS MARKET SIZE, BY GENERATION OF CEPHALOSPORIN, 2018-2030 (USD MILLION)
  • TABLE 162. SOUTH AFRICA CEPHALOSPORIN DRUGS MARKET SIZE, BY DRUG ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 163. SOUTH AFRICA CEPHALOSPORIN DRUGS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 164. SOUTH AFRICA CEPHALOSPORIN DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 165. SPAIN CEPHALOSPORIN DRUGS MARKET SIZE, BY GENERATION OF CEPHALOSPORIN, 2018-2030 (USD MILLION)
  • TABLE 166. SPAIN CEPHALOSPORIN DRUGS MARKET SIZE, BY DRUG ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 167. SPAIN CEPHALOSPORIN DRUGS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 168. SPAIN CEPHALOSPORIN DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 169. SWEDEN CEPHALOSPORIN DRUGS MARKET SIZE, BY GENERATION OF CEPHALOSPORIN, 2018-2030 (USD MILLION)
  • TABLE 170. SWEDEN CEPHALOSPORIN DRUGS MARKET SIZE, BY DRUG ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 171. SWEDEN CEPHALOSPORIN DRUGS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 172. SWEDEN CEPHALOSPORIN DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 173. SWITZERLAND CEPHALOSPORIN DRUGS MARKET SIZE, BY GENERATION OF CEPHALOSPORIN, 2018-2030 (USD MILLION)
  • TABLE 174. SWITZERLAND CEPHALOSPORIN DRUGS MARKET SIZE, BY DRUG ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 175. SWITZERLAND CEPHALOSPORIN DRUGS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 176. SWITZERLAND CEPHALOSPORIN DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 177. TURKEY CEPHALOSPORIN DRUGS MARKET SIZE, BY GENERATION OF CEPHALOSPORIN, 2018-2030 (USD MILLION)
  • TABLE 178. TURKEY CEPHALOSPORIN DRUGS MARKET SIZE, BY DRUG ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 179. TURKEY CEPHALOSPORIN DRUGS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 180. TURKEY CEPHALOSPORIN DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 181. UNITED ARAB EMIRATES CEPHALOSPORIN DRUGS MARKET SIZE, BY GENERATION OF CEPHALOSPORIN, 2018-2030 (USD MILLION)
  • TABLE 182. UNITED ARAB EMIRATES CEPHALOSPORIN DRUGS MARKET SIZE, BY DRUG ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 183. UNITED ARAB EMIRATES CEPHALOSPORIN DRUGS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 184. UNITED ARAB EMIRATES CEPHALOSPORIN DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 185. UNITED KINGDOM CEPHALOSPORIN DRUGS MARKET SIZE, BY GENERATION OF CEPHALOSPORIN, 2018-2030 (USD MILLION)
  • TABLE 186. UNITED KINGDOM CEPHALOSPORIN DRUGS MARKET SIZE, BY DRUG ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 187. UNITED KINGDOM CEPHALOSPORIN DRUGS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 188. UNITED KINGDOM CEPHALOSPORIN DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 189. CEPHALOSPORIN DRUGS MARKET, FPNV POSITIONING MATRIX, 2022
  • TABLE 190. CEPHALOSPORIN DRUGS MARKET SHARE, BY KEY PLAYER, 2022
  • TABLE 191. CEPHALOSPORIN DRUGS MARKET LICENSE & PRICING
目次
Product Code: MRR-433AB1DC28F4

The Global Cephalosporin Drugs Market is forecasted to grow significantly, with a projected USD 11.37 billion in 2023 at a CAGR of 6.64% and expected to reach a staggering USD 17.86 billion by 2030.

The Cumulative Impact of COVID-19, the Russia-Ukraine Conflict, and High Inflation is expected to have significant long-term effects on the Global Cephalosporin Drugs Market. The ongoing research considers the changes in consumer behavior, supply chain disruptions, and government interventions caused by the pandemic. Similarly, the report considers the ongoing political and economic uncertainty in Eastern Europe caused by the Russia-Ukraine Conflict and its potential implications for demand-supply balances, pressure on pricing variants, and import/export and trading. Additionally, the report addresses the impact of High Inflation on the global economy and details fiscal policies measuring and reducing its effects on demand, supply, cash flow, and currency exchange.

Market Segmentation & Coverage:

This research report categorizes the Global Cephalosporin Drugs Market in order to forecast the revenues and analyze trends in each of following sub-markets:

Based on Generation of Cephalosporin, market is studied across Fifth-Generation, First-Generation, Fourth-Generation, Second-Generation, and Third-Generation. The First-Generation is projected to witness significant market share during forecast period.

Based on Drug Administration, market is studied across Injection and Oral. The Injection is projected to witness significant market share during forecast period.

Based on Prescription Type, market is studied across OTC Drugs and Prescription Drugs. The Prescription Drugs is projected to witness significant market share during forecast period.

Based on Application, market is studied across Ear Infection, Respiratory Tract Infection, Skin Infection, and Urinary Tract Infection. The Ear Infection is projected to witness significant market share during forecast period.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom. The Americas commanded largest market share of 38.75% in 2022, followed by Europe, Middle East & Africa.

Market Statistics:

The report provides market sizing and forecasts across 7 major currencies - USD, EUR, JPY, GBP, AUD, CAD, and CHF; multiple currency support helps organization leaders to make well-informed decisions. In this report, 2018 to 2021 are considered as historical years, 2022 is base year, 2023 is estimated year, and years from 2024 to 2030 are considered as forecast period.

FPNV Positioning Matrix:

The FPNV Positioning Matrix is essential for assessing the Global Cephalosporin Drugs Market. It provides a comprehensive evaluation of vendors by examining key metrics within Business Strategy and Product Satisfaction, allowing users to make informed decisions based on their specific needs. This advanced analysis then organizes these vendors into four distinct quadrants, which represent varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital(V).

Market Share Analysis:

The Market Share Analysis offers an insightful look at the current state of vendors in a particular market space. By comparing vendor contributions to overall revenue, customer base, and other key metrics, we can give companies a greater understanding of their performance and what they are up against when competing for market share. The analysis also sheds light on just how competitive any given sector is about accumulation, fragmentation dominance, and amalgamation traits over the base year period studied.

The report provides insights on the following pointers:

1. Market Penetration: Provides comprehensive information on the market offered by the key players

2. Market Development: Provides in-depth information about lucrative emerging markets and analyzes penetration across mature segments of the markets

3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments

4. Market Trends: Provides comprehensive understanding of the Cumulative Impact of COVID-19, the Russia-Ukraine Conflict, and the High Inflation

5. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players

6. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:

1. What is the market size and forecast of the Global Cephalosporin Drugs Market?

2. What are the inhibiting factors and impact of COVID-19 shaping the Global Cephalosporin Drugs Market during the forecast period?

3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Cephalosporin Drugs Market?

4. What is the competitive strategic window for opportunities in the Global Cephalosporin Drugs Market?

5. What are the technology trends and regulatory frameworks in the Global Cephalosporin Drugs Market?

6. What is the market share of the leading vendors in the Global Cephalosporin Drugs Market?

7. What modes and strategic moves are considered suitable for entering the Global Cephalosporin Drugs Market?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Limitations
  • 1.7. Assumptions
  • 1.8. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

  • 4.1. Introduction
  • 4.2. Cephalosporin Drugs Market, by Generation of Cephalosporin, 2022 vs 2030
  • 4.3. Cephalosporin Drugs Market, by Drug Administration, 2022 vs 2030
  • 4.4. Cephalosporin Drugs Market, by Prescription Type, 2022 vs 2030
  • 4.5. Cephalosporin Drugs Market, by Application, 2022 vs 2030
  • 4.6. Cephalosporin Drugs Market, by Region, 2022 vs 2030

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Growing cases of bacterial infection such as skin and UTIs
      • 5.1.1.2. Continuous focus on R&D and clinical trials
      • 5.1.1.3. Widespread application of a combination therapy
    • 5.1.2. Restraints
      • 5.1.2.1. Side effects related to cephalosporins drugs
    • 5.1.3. Opportunities
      • 5.1.3.1. Increasing investment by pharmaceutical companies & associations to boost the antibiotic drug development
      • 5.1.3.2. Revised government regulation in favor of antibiotic drugs
    • 5.1.4. Challenges
      • 5.1.4.1. Limited consciousness among the people and unbalanced demand & supply in rural or remote areas
  • 5.2. Market Trends
  • 5.3. Cumulative Impact of COVID-19
  • 5.4. Cumulative Impact of Russia-Ukraine Conflict
  • 5.5. Cumulative Impact of High Inflation
  • 5.6. Porter's Five Forces Analysis
    • 5.6.1. Threat of New Entrants
    • 5.6.2. Threat of Substitutes
    • 5.6.3. Bargaining Power of Customers
    • 5.6.4. Bargaining Power of Suppliers
    • 5.6.5. Industry Rivalry
  • 5.7. Value Chain & Critical Path Analysis
  • 5.8. Regulatory Framework
  • 5.9. Client Customization

6. Cephalosporin Drugs Market, by Generation of Cephalosporin

  • 6.1. Introduction
  • 6.2. Fifth-Generation
  • 6.3. First-Generation
  • 6.4. Fourth-Generation
  • 6.5. Second-Generation
  • 6.6. Third-Generation

7. Cephalosporin Drugs Market, by Drug Administration

  • 7.1. Introduction
  • 7.2. Injection
  • 7.3. Oral

8. Cephalosporin Drugs Market, by Prescription Type

  • 8.1. Introduction
  • 8.2. OTC Drugs
  • 8.3. Prescription Drugs

9. Cephalosporin Drugs Market, by Application

  • 9.1. Introduction
  • 9.2. Ear Infection
  • 9.3. Respiratory Tract Infection
  • 9.4. Skin Infection
  • 9.5. Urinary Tract Infection

10. Americas Cephalosporin Drugs Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Cephalosporin Drugs Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Cephalosporin Drugs Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. FPNV Positioning Matrix
  • 13.2. Market Share Analysis, By Key Player
  • 13.3. Competitive Scenario Analysis, By Key Player

14. List of Company Mentioned

15. Appendix

  • 15.1. Discussion Guide
  • 15.2. License & Pricing